Anastrozole Arimidex Powder

Anastrozole Arimidex Powder Quick Details:

There are several Aromatase Inhibitors available, Femara (Letrozole), Aromasin (Exemestane) and Arimidex (Anastrozole) being the most common. All three are very similar and while all three carry slight differences that make them unique many agree Arimidex may be the most valuable of all. Arimidex is generally the modern preferred anti-estrogen in breast cancer treatment, as well as the preferred AI in low testosterone treatment plans. For the anabolic steroid user, it is highly efficient and should be the only AI you need. However, in cases where gynecomastia symptoms are already beginning to show, many report heavy Letrozole doses to be the answer to the remedy, where in time switching to Arimidex as a preventative measure. However, in the end, for the performance enhancing athlete, he may need to try all three at varying times to find which AI works best for him.

Anastrozole Arimidex Powder Functions & Traits:

The functions and traits of Arimidex although powerful are extremely simple. As an AI Arimidex functions by blocking the aromatase enzyme, which is in turn responsible for the production of estrogen. By inhibiting the aromatase process, Arimidex will lower the body’s serum estrogen levels; in fact, a total suppression of estrogen by 80% has been well noted with this AI. This will prove very beneficial to numerous breast cancer patients and extremely valuable to many anabolic steroid users.

Arimidex also has the ability to stimulate the release of Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH), two hormones essential to natural testosterone production. This has led some physicians to use the AI in low testosterone treatment plans in place of testosterone, but it’s generally not the best choice. Arimidex in a low testosterone plan is generally better served in conjunction with testosterone therapy. We will look more into this when we discuss the effects of Arimidex later on.

Benefits of Anastrozole Arimidex Powder:

The large ATAC (Arimidex, Tamoxifen Alone or in Combination) trial compared Arimidex to tamoxifen after surgery. The researchers wanted to know how the medicines worked by themselves as well as together to see which combination would be the best treatment for postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer. Based on the results of this trial, giving Arimidex and tamoxifen at the same time isn’t recommended.

The ATAC study found that 5 years of Arimidex is better than 5 years of tamoxifen as the first hormonal therapy for postmenopausal women with early-stage, hormone-receptor-positive breast cancer. Arimidex is better than tamoxifen for:

increasing the time before the cancer comes back in those who experience recurrence
reducing the risk of the cancer spreading to other parts of the body
reducing the risk of a new cancer developing in the other breast
Research presented at the 2013 San Antonio Breast Cancer Symposium showed that Arimidex can lower the risk of first-time, hormone-receptor-positive breast cancer in postmenopausal women at high risk who haven’t been diagnosed. Arimidex isn’t approved by the FDA for this use, but doctors may consider it a good alternative to other hormonal therapies approved to reduce risk in high-risk women.

It’s possible that the FDA may approve Arimidex to be used to reduce risk in high-risk postmenopausal women who haven’t been diagnosed.

For more details, plz contact us freely,  thanks for your kind attention. 🙂